HALO
Another quarter, another flex
Halozyme came out swinging with record second-quarter 2026 results, and the numbers weren’t subtle. Total revenue jumped 48% year over year to $481 million, while royalty revenue climbed 50% to $308 million. In investor-speak: the engine is humming, and it’s not just one-off noise.
The real kicker: guidance went up
Management didn’t stop at the beat. It also raised full-year 2026 guidance across the board:
- Total revenue now seen at $1.835 billion to $1.910 billion
- Royalty revenue projected at $1.220 billion to $1.245 billion
- Adjusted EBITDA expected at $1.225 billion to $1.280 billion
- Non-GAAP diluted EPS guided to $8.65 to $9.00
That’s the kind of update that usually gets investors leaning in a little closer. Higher guidance suggests the company thinks the good times aren’t a fluke — they’re a trend.
More partnerships, more proof points
Halozyme also said it signed five new ENHANZE and Hyperc collaboration agreements year-to-date, already topping its full-year goal of three. That matters because these deals help show the platform still has plenty of room to expand, which is a fancy way of saying this growth story may not be running out of chapters anytime soon.
Big picture: when a biotech-like platform company beats, raises, and adds new deal momentum all in one quarter, the market tends to pay attention. The stock may not moon on vibes alone, but this report gives it some very real fuel.